GEAP202416596A - Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof - Google Patents

Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Info

Publication number
GEAP202416596A
GEAP202416596A GEAP202416596A GEAP2024016596A GEAP202416596A GE AP202416596 A GEAP202416596 A GE AP202416596A GE AP202416596 A GEAP202416596 A GE AP202416596A GE AP2024016596 A GEAP2024016596 A GE AP2024016596A GE AP202416596 A GEAP202416596 A GE AP202416596A
Authority
GE
Georgia
Prior art keywords
tl1a
compositions
tnf
ligand
humanized antibodies
Prior art date
Application number
GEAP202416596A
Other languages
English (en)
Georgian (ka)
Inventor
Stephan R Targan
Janine Bilsborough
Olivier Laurent
Robert Payne
Mark Manning
Lauren Otsuki
Allison Luo
Bradley Henkle
Original Assignee
Cedars Sinai Medical Center
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Prometheus Biosciences Inc filed Critical Cedars Sinai Medical Center
Publication of GEAP202416596A publication Critical patent/GEAP202416596A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
GEAP202416596A 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof GEAP202416596A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163150825P 2021-02-18 2021-02-18
US202163180892P 2021-04-28 2021-04-28
US202163226037P 2021-07-27 2021-07-27
US202163285781P 2021-12-03 2021-12-03

Publications (1)

Publication Number Publication Date
GEAP202416596A true GEAP202416596A (en) 2024-10-28

Family

ID=82931032

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202416596A GEAP202416596A (en) 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
GEAP202316354A GEAP202316354A (en) 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP202316354A GEAP202316354A (en) 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Country Status (19)

Country Link
US (1) US20240309104A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294444A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506940A (cg-RX-API-DMAC7.html)
KR (1) KR20230157973A (cg-RX-API-DMAC7.html)
AU (1) AU2022223420A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016672A2 (cg-RX-API-DMAC7.html)
CA (1) CA3207817A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002424A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023011969A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230436A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000162A (cg-RX-API-DMAC7.html)
EC (1) ECSP23070237A (cg-RX-API-DMAC7.html)
GE (2) GEAP202416596A (cg-RX-API-DMAC7.html)
IL (1) IL305312A (cg-RX-API-DMAC7.html)
JO (1) JOP20230185A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009622A (cg-RX-API-DMAC7.html)
PE (1) PE20231681A1 (cg-RX-API-DMAC7.html)
TW (1) TW202246322A (cg-RX-API-DMAC7.html)
WO (1) WO2022178159A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
US20260216326A1 (en) * 2022-12-22 2026-07-30 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
EP4665767A2 (en) * 2023-02-17 2025-12-24 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the bile duct
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN105814081B (zh) * 2013-11-13 2021-02-02 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
US10968279B2 (en) * 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN119735681A (zh) * 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
TW202600603A (zh) * 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途

Also Published As

Publication number Publication date
BR112023016672A2 (pt) 2023-11-21
AU2022223420A1 (en) 2023-09-21
WO2022178159A1 (en) 2022-08-25
CR20230436A (es) 2023-11-01
CA3207817A1 (en) 2022-08-25
TW202246322A (zh) 2022-12-01
IL305312A (en) 2023-10-01
EP4294444A4 (en) 2025-04-16
JP2024506940A (ja) 2024-02-15
CL2023002424A1 (es) 2024-01-05
JOP20230185A1 (ar) 2023-08-09
KR20230157973A (ko) 2023-11-17
DOP2023000162A (es) 2023-10-15
EP4294444A1 (en) 2023-12-27
MX2023009622A (es) 2023-08-28
US20240309104A1 (en) 2024-09-19
GEAP202316354A (en) 2023-12-25
PE20231681A1 (es) 2023-10-19
ECSP23070237A (es) 2023-10-31
CO2023011969A2 (es) 2023-09-29

Similar Documents

Publication Publication Date Title
ZA202204557B (en) Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
GEAP202316354A (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
GEAP202616911A (en) Anti-cd30l antibodies and uses thereof
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
WO2019209995A3 (en) Optimized anti-tl1a antibodies
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
EA201892790A1 (ru) Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний
MX2022008951A (es) Composiciones de inhibidores de molecula peque?a del receptor de quimiocina c-c tipo 9 (ccr9) y anticuerpos bloqueadores anti- 4?7 integrina para usarse en el tratamiento de enfermedad inflamatoria de intestino.
JOP20210030A1 (ar) مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
MX2025001038A (es) Anticuerpos anti-cd30l, formulaciones de estos, y uso de los mismos
NZ787680A (en) Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
BR112022019958A2 (pt) Composições e métodos para o tratamento de doenças inflamatórias do intestino utilizando anticorpos inibidores de ccr9 e anticorpos de bloqueio anti-il -23
MX2025001041A (es) Anticuerpos anti-tl1a para el tratamiento de la colitis ulcerosa y la enfermedad de crohn
MX379140B (es) Sal de etano-sulfonato del derivado de quinolina.
EA201890741A1 (ru) Биспецифические антитела против cgrp/il-23 и их применения
MX2022011953A (es) Composicion para controlar el olor y alfombra que tiene una propiedad durable de control de olor.
DOP2023000160A (es) Anticuerpos anti-cd30l y usos de estos
HK40101325A (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
AR133812A1 (es) INHIBICIÓN DE LA INTEGRINA a4b7 HUMANA
CO2026003130A2 (es) Inhibición de la integrina α4β7 humana
EA201992625A1 (ru) Способы и композиции для лечения воспалительных расстройств желудочно-кишечного тракта